Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Opioid withdrawal syndrome-associated cognitive impairment: A narrative review.

Created on 18 Sep 2026

Authors

Faizan Khan, Nazli Tunali, R Andrew Chambers

Published in

The American journal on addictions. Sep 17, 2026. Epub Sep 17, 2026.

Abstract

Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS. This paper explores accumulating literature describing Opioid Withdrawal Syndrome-associated Cognitive Impairment (OWSCI) which may inform clinical care and therapeutics research.
A search of studies published before August 2026 was conducted via PubMed and Google Scholar (309 and 626 papers screened) via crossing "cognition" with "opioid withdrawal," "early opioid abstinence," "opioid use," or "opioid addiction." Bibliography searches were also conducted of core target papers defined as human adult studies measuring cognition during OWS from 1 to 15 days after last opioid use.
Only seven studies were identified meeting core criteria. These varied considerably by design, patient samples, comorbidities, timing and methods of cognitive testing, and OWS treatments. The evidence thus far suggests OWSCI is a measurable transient feature of OWS that overlays, and is modulated by, a wide range of clinical variables including opioid history, medication treatments, other addictions, and neuropsychiatric comorbidities.
Future studies on OWSCI entailing more rigorous experimental controls and standardizations, while accounting for diverse comorbidities and OWS treatments, are needed to more fully characterize OWSCI.
Growing data on OWSCI are deepening our understanding of neurobiological and clinical dimensions of OWS, potentially providing clues for improving treatments for patients transitioning through OWS into opioid-free recoveries.

PMID:
42755023
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement